Latest News
View All OAR 2023 cover

View OUR 2023 annual report

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Read more
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Read more
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Read more

Oncology Focused, Patient Centric

We are committed to the development of novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with standard-of-care therapies to provide improved outcomes to patients.

Our Clinical Trials
Our Clinical Trials
/pipeline/clinical-trials
Hematologic Malignancies
Hematologic Malignancies
/focus/hematologic-malignancies
Solid Tumors
Solid Tumors
/focus/solid-tumors
Delivering Benefit to Patients
Patients

Delivering Benefit to Patients

Our driving purpose and principle is simple: deliver novel and differentiated cancer therapies that provide improved outcomes for patients.
Patients